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Abstract
Background: Overdiagnosis in breast cancer screening is a controversial topic. One difficulty in estimation of
overdiagnosis is the separation of overdiagnosis from lead time that is the advance in the time of diagnosis of
cancers, which confers an artificial increase in incidence when a screening programme is introduced.
Methods: We postulated a female population aged 50-79 with a similar age structure and age-specific breast
cancer incidence as in England and Wales before the screening programme. We then imposed a two-yearly
screening programme; screening women aged 50-69, to run for twenty years, with exponentially distributed lead
time with an average of 40 months in screen-detected cancers. We imposed no effect of the screening on
incidence other than lead time.
Results: Comparison of age- and time-specific incidence between the screened and unscreened populations
showed a major effect of lead time, which could only be adjusted for by follow-up for more than two decades
and including ten years after the last screen. From lead time alone, twenty-year observation at ages 50-69 would
confer an observed excess incidence of 37%. The excess would only fall below 10% with 25 years or more follow-
up. For the excess to be nullified, we would require 30 year follow-up including observation up to 10 years above
the upper age limit for screening.
Conclusion: Studies using shorter observation periods will overestimate overdiagnosis by inclusion of cancers
diagnosed early due to lead time among the nominally overdiagnosed tumours.
Introduction
The issue of overdiagnosis in breast cancer screening is
a topic of much interest and controversy [1-3]. Over-
diagnosis is usually defined as the diagnosis as a result
of screening of cancer that would never have been diag-
nosed in the woman’s life in the absence of screening
[1]. In theory, overdiagnosis can be estimated by com-
parison of incidence in a randomized trial of screening,
but this would require that the control group was never
screened and that both intervention and control groups
were followed up to expiry or for more than at least two
decades. In practice, none of the trials satisfy both of
these criteria [4]. Consequently, overdiagnosis rates are
usually estimated on the basis of changes in breast can-
cer incidence following the introduction of screening
services in a population setting [1-3,5,6]. There is no
uniform method of estimation, and, consequently, esti-
mates vary considerably, from less than 5% to around
50% [1].
One of the first observable effects of breast screening is
the capability to diagnose cancer before it would have
occurred symptomatically, since screening works by diag-
nosing breast cancer at an earlier and more treatable
stage [7]. The temporal advance in the time of diagnosis
is known as the lead time. A major complication of esti-
mating overdiagnosis is taking account of lead time to
disentangle overdiagnosed from early-diagnosed cases
[1]. Overdiagnosis can be thought of as cases whose lead
time exceeds their remaining years of life. Cases whose
lead time does not exceed their future lifetime will cause
an increase in incidence to be observed but should not
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be included in the estimation of overdiagnosis. There is
disagreement about the importance of lead time [8,9],
but there is no doubt that the phenomenon exists, since
incidence of breast cancer after a screen is considerably
lower than in the absence of screening, indicating that
many tumors have their period of diagnosis advanced
[10].
In this article, we generate a set of breast cancer inci-
dence figures, by individual year of age and individual
calendar year, in the absence of screening. These are
based approximately on the population of age 50 to 79
and the age-specific incidence of breast cancer in the
late 1980s in the UK, just before the screening program
started. We then generate the effect on occurrence of
breast cancer of a 2-yearly screening program from age
50 to 69, assuming only lead time and no overdiagnosis.
We use the difference between the two to evaluate the
reliability of different strategies for adjusting for lead
time in estimation of overdiagnosis.
Materials and methods
We postulated a population of age 50 to 79 and of size
and structure similar to those prevailing in the female
population in England and Wales in the late 1980s
[11,12]. We further postulated that invasive breast can-
cer incidence rates in the absence of screening would
increase from 158.4 per 100,000 person-years at age 50
to 272.7 per 100,000 at age 79, again corresponding
roughly to those prevailing in England and Wales in the
years immediately prior to the screening program
[11,12]. The population, incidence rates, and numbers of
cases are shown by individual year of age in Table 1.
For simplicity, we assumed that in the absence of
screening, the population age structure and age-specific
breast cancer incidence rates remain stable for the fol-
lowing 30 years. Thus, the same number of cases in
each individual year of age occurred for the following 30
years.
We then assumed the introduction of a screening pro-
gram with 2-yearly screening applied to all women cur-
rently 50 to 69 years old, at years 1, 3, 5, and so on up
to year 19 (that is, 10 rounds of screening in all). We
assumed that the only effect of screening on incidence
of breast cancer was one of lead time. We postulated
that in screening a population age x in year y we would
find 86% of the cancers which would have occurred in
age x+1, year y+1, 64% of tumors which would have
occurred in age x+2, year y+2, and so on up to 7% of
the tumors from age x+10, y+11, as shown in Table 2.
These figures correspond to an average lead time of
around 40 months, which is consistent with the esti-
mates for this age group [13-16], most of which also
found screening sensitivities of close to 100%. For math-
ematical details, see the Appendix.
Table 1 Postulated incidence of breast cancer by
individual year of age in the absence of screening
Age, years Population Incidence, per 100,000 Number of cases
50 253,157 158.4 401
51 252,774 162.2 410
52 253,012 166.0 420
53 253,239 169.8 430
54 253,026 173.5 439
55 262,267 177.3 465
56 261,879 181.0 474
57 261,905 184.8 484
58 261,780 191.0 500
59 262,170 197.2 517
60 275,947 203.3 561
61 275,895 209.5 578
62 275,846 215.7 595
63 276,020 218.1 602
64 276,191 220.5 609
65 231,943 222.9 517
66 232,135 225.3 523
67 231,884 227.7 528
68 232,059 232.7 540
69 231,805 237.7 551
70 231,974 242.7 563
71 232,136 247.7 575
72 231,896 252.7 586
73 232,003 255.6 593
74 231,811 258.4 599
75 189,820 261.3 496
76 190,080 264.1 502
77 189,888 267.0 507
78 190,070 269.9 513
79 189,952 272.7 518
Table 2 Proportion of cancers with time of diagnosis
advanced to the year of screening, by year*
Years after
screen
Percentage of diagnoses advanced to screen
year
1 86
2 64
3 48
4 35
5 26
6 20
7 15
8 11
9 9
10 7
By year at which diagnosis would have taken place in the absence of
screening
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We then compared the numbers of cancers between
the screening and no-screening scenarios, for different
age groups and periods of observation, to estimate the
excess incidence that would be observed as a result of
lead time alone and to evaluate the likely efficacy of var-
ious methods of taking account of lead time. We also
calculated the resulting estimates for different strategies
used in the past to take lead time into account. These
include considering incidence up to 5 and 10 years after
the upper age limit for screening and comparing breast
cancer incidence in the screened population with the
corresponding incidence of subjects in the unscreened
population who are 2 to 5 years older [5,6]. This was
solely a modeling study that involved no experimental
work on human or animal subjects. No ethical approval
or consent was required.
Results
Table 3 shows the numbers of cancers diagnosed over
30 years, by calendar year and year of age, under the
scenario of 2-yearly screening of women 50 to 69 years
old for 10 rounds (the first 20 years) as described above.
The corresponding numbers of cancers in the absence
of screening would simply be the column of cancers in
Table 1, 401, 410, and so on, repeated 30 times. The
lead-time effect can be seen for age 50, year 1, for
example, as
410 + 0.86 × 410 + 0.64 × 420 + · · · + 0.07 × 561 = 1, 812.
Thus, the effect of lead time is to shift cancers along
the diagonal of the table, upward and leftward. This
reflects the fact that earlier detection brings forward the
diagnosis of the tumor both in calendar period and age.
For example, without screening in year 1, there would
be 4,540 cancers diagnosed at ages 50 to 59; with
screening, there would be 20,756. Conversely, in year 10
at ages 70 to 79, there would be 5,452 cancers diag-
nosed without screening but only 3,268 with screening.
This shift in age and time of diagnosis also means that
if incidence is increasing with age, with time, or with
both, then the observed excess due to lead time will be
larger. Figure 1 shows the cumulative numbers of breast
cancer cases observed in the cohort of age 50 at year 1,
over 30 years, with and without screening. The inci-
dences separate dramatically, in the first 10 years, and
the disparity remains roughly constant over the follow-
ing 10 years; then the two cumulative graphs come
together at 30 years. This demonstrates that the only
phenomenon generated by the screening in this scenario
is lead time. The screening diagnoses many cancers ear-
lier than they would have been diagnosed in the absence
of screening, but after the screening stops, there is
a deficit of cases in the screened group and the
unscreened group ‘catches up’.
Some researchers attempt to control for lead time by
comparing incidence up to 10 years above the upper age
limit for screening [5]. The rationale for this approach is
that an excess of cases observed at screening ages
because of lead time will be balanced by a corresponding
deficit in cases above the screening age range. Table 4
shows the cumulative numbers of cancers with and with-
out screening, by years of follow-up and upper age limit.
Clearly, when the age range for screening alone is
observed, lead time confers a substantial increase in
observed cases, which remains substantial 10 years after
the program has stopped. From lead time alone, 20-year
observation at ages 50 to 69 would confer an observed
excess incidence of 37% in the screened population. The
excess would only fall below 10% with a follow-up of 25
years or more. For the excess to be nullified, or almost
nullified, we would require a 30-year follow-up, including
observation up to 10 years above the upper age limit for
screening. This is because lead time shifts the diagnosis
not only in terms of age of the subject but also in terms
of the calendar year of diagnosis.
Another strategy sometimes employed to account for
lead time is to compare the incidence in the screened
population with the corresponding incidence of subjects
in the unscreened population who are 2 to 5 years older
[5,6]. Table 5 shows the incidence per 100,000 person-
years in 5-year age groups and time periods in the
screened and unscreened populations. Note that because
alternate 5-year periods contain two screens and three
screens, the overall incidence in the screened population
fluctuates from period to period. Note also that within
5-year periods there is no monotonic increase in inci-
dence with age, because some of the older age groups
have cases shifted to younger groups because of lead
time. If we compare the cumulative incidence over 10
years between the age group of 50 to 69 in the screened
population and the age group of 55 to 74 in the
unscreened population, using Table 5 data, we would
observe 3,000 cases per 100,000 women in the screened
population and 2,190 in the latter, an excess of 37%. At
20 years, we would observe 5,415 cases per 100,000
women in the screened population and 4,380 in the
unscreened population, an excess of 24%. At 30 years,
the cumulative incidence figures would be 6,865 and
6,570, an excess of 4%.
A more exact ‘aging’ adjustment for lead time might be
to compare the cumulative incidence of a screened
cohort with that of an unscreened cohort that is 5 years
older. Figure 2 shows the cumulative incidence per
100,000 women up to year 25 (not 30, since we do not
have data for ages 80 and above) for ages 50 to 54 at the
start of the follow-up period in the screened population
and 55 to 59 in the unscreened population. The inci-
dence curves come together only at 25 years. There is
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Table 3 Numbers of tumors diagnosed by age and year in a 2-yearly screening program
Age, years Calendar year
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
50 1,812 401 1,812 401 1,812 401 1,812 401 1,812 401 1,812 401 1,812 401 1,812 401 1,812 401 1,812 401 401 401 401 401 401 401 401 401 401 401
51 1,863 57 1,863 57 1,863 57 1,863 57 1,863 57 1,863 57 1,863 57 1,863 57 1,863 57 1,863 57 410 410 410 410 410 410 410 410 410 410
52 1,919 59 1,242 59 1,242 59 1,242 59 1,242 59 1,242 59 1,242 59 1,242 59 1,242 59 1,242 59 151 420 420 420 420 420 420 420 420 420
53 1,979 60 1,282 31 1,282 31 1,282 31 1,282 31 1,282 31 1,282 31 1,282 31 1,282 31 1,282 31 155 224 430 430 430 430 430 430 430 430
54 2,045 61 1,326 32 1,119 32 1,119 32 1,119 32 1,119 32 1,119 32 1,119 32 1,119 32 1,119 32 103 228 285 439 439 439 439 439 439 439
55 2,111 65 1,364 34 1,149 25 1,149 25 1,149 25 1,149 25 1,149 25 1,149 25 1,149 25 1,149 25 109 179 302 344 465 465 465 465 465 465
56 2,164 66 1,397 35 1,176 26 1,087 26 1,087 26 1,087 26 1,087 26 1,087 26 1,087 26 1,087 26 89 182 246 351 379 474 474 474 474 474
57 2,224 68 1,433 35 1,204 26 1,112 22 1,112 22 1,112 22 1,112 22 1,112 22 1,112 22 1,112 22 91 158 252 304 387 411 484 484 484 484
58 2,288 70 1,467 36 1,229 27 1,133 23 1,098 23 1,098 23 1,098 23 1,098 23 1,098 23 1,098 23 83 164 231 315 356 425 445 500 500 500
59 2,351 72 1,497 38 1,249 28 1,149 24 1,113 22 1,113 22 1,113 22 1,113 22 1,113 22 1,113 22 86 154 239 296 368 400 460 470 517 517
60 2,408 79 1,516 41 1,261 30 1,157 26 1,119 23 1,112 23 1,112 23 1,112 23 1,112 23 1,112 23 87 167 241 321 371 434 464 511 522 561
61 2,422 81 1,516 42 1,259 31 1,155 26 1,115 24 1,108 24 1,108 24 1,108 24 1,108 24 1,108 24 90 172 249 331 383 447 478 526 538 578
62 2,416 83 1,505 43 1,249 32 1,146 27 1,105 25 1,098 25 1,098 25 1,098 25 1,098 25 1,098 25 92 177 256 341 394 460 492 541 553 595
63 2,385 84 1,485 44 1,234 32 1,133 28 1,094 25 1,087 25 1,087 25 1,087 25 1,087 25 1,087 25 93 179 259 345 399 466 498 548 560 602
64 2,333 85 1,462 44 1,219 33 1,122 28 1,086 25 1,079 25 1,079 25 1,079 25 1,079 25 1,079 25 94 181 262 349 403 471 504 554 566 609
65 2,260 72 1,442 38 1,208 28 1,114 24 1,079 22 1,073 22 1,073 22 1,073 22 1,073 22 1,073 22 80 154 223 296 342 400 428 470 481 517
66 2,286 73 1,456 38 1,218 28 1,123 24 1,088 22 1,081 22 1,081 22 1,081 22 1,081 22 1,081 22 81 156 225 299 346 405 433 476 486 523
67 2,313 74 1,470 38 1,228 28 1,131 24 1,095 22 1,089 22 1,089 22 1,089 22 1,089 22 1,089 22 82 157 227 302 350 408 437 480 491 528
68 2,340 76 1,482 39 1,235 29 1,136 25 1,099 23 1,093 23 1,093 23 1,093 23 1,093 23 1,093 23 84 161 232 309 358 418 447 491 502 540
69 2,360 77 1,487 40 1,237 30 1,136 25 1,098 23 1,092 23 1,092 23 1,092 23 1,092 23 1,092 23 85 164 237 315 365 426 456 501 512 551
70 563 79 203 41 132 30 105 26 94 23 87 23 87 23 87 23 87 23 87 23 87 168 242 322 373 435 466 512 524 563
71 575 575 207 299 135 221 108 188 96 171 89 171 247 329 381 445 89 171 89 171 89 171 247 329 381 445 476 523 535 575
72 586 586 586 305 381 225 305 192 271 174 252 174 252 335 388 453 485 174 252 174 252 174 252 335 388 453 485 533 545 586
73 593 593 593 593 385 439 308 373 274 339 255 339 255 339 393 459 491 540 255 339 255 339 255 339 393 459 491 540 551 593
74 599 599 599 599 599 443 479 377 426 343 397 343 397 343 397 463 496 545 557 343 397 343 397 343 397 463 496 545 557 599
75 496 496 496 496 496 496 397 422 353 384 328 384 328 384 328 384 411 451 461 496 328 384 328 384 328 384 411 451 461 496
76 502 502 502 502 502 502 502 427 447 388 416 388 416 388 416 388 416 457 467 502 502 388 416 388 416 388 416 457 467 502
77 507 507 507 507 507 507 507 507 451 461 420 461 420 461 420 461 420 461 472 507 507 507 420 461 420 461 420 461 472 507
78 513 513 513 513 513 513 513 513 513 467 477 467 477 467 477 467 477 467 477 513 513 513 513 467 477 467 477 467 477 513
79 518 518 518 518 518 518 518 518 518 518 482 518 482 518 482 518 482 518 482 518 518 518 518 518 482 518 482 518 482 518
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Figure 1 Expected cumulative incidence over ages 50 to 79 in a cohort of women of age 50 at the start, with and without 2-yearly
screening from age 50 to 69.
Table 4 Cumulative numbers of breast cancer cases observed with and without screening
Age range observed, years Years of follow-up Number of cases Observed percentage excess
Without screening With screening incidence With screening
50-69 5 50,270 102,380 102
10 101,440 153,460 51
15 152,160 226,680 49
20 202,880 277,060 37
25 253,600 304,080 20
30 304,320 351,260 15
50-74 5 65,300 113,400 74
10 130,600 170,500 31
15 195,900 250,100 28
20 261,200 307,675 18
25 326,500 341,975 5
30 391,800 402,100 3
50-79 5 77,980 126,069 62
10 155,960 195,018 25
15 233,940 285,435 22
20 311,920 354,714 14
25 389,900 400,239 3
30 467,880 472,014 1
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still a substantial excess in the screened population at
20 years.
Discussion
We posited a population of age 50 to 79 with age distri-
bution and breast cancer incidence similar to those that
prevailed in the UK before the NHS Breast Screening
Programme was initiated. We assumed that age-specific
incidence in an unscreened population would remain
unchanged over 30 years. We then imposed a screening
program with 2-yearly screening for 20 years from age
50 to 69 (as is common in Europe). We calculated the
incidence in the screened population, assuming that the
only influence of screening on incidence was lead time,
using lead-time parameters similar to those observed in
a large breast screening trial [13,14]. Thus, we calculated
the expected effects on incidence from lead time alone,
with no influence of overdiagnosis or changes in under-
lying risk.
The most important finding was that lead time can be
expected to add substantially to observed incidence in a
screened population. Although the increase is greatest in
the early years of the program, there is still a substantial
excess at long-term follow-up. From Table 4, in the
screened age group, 50 to 69, a 37% excess cumulative
incidence was apparent at 20 years, and a 15% excess at
30 years, 10 years after the program stopped. Thus, the
first conclusions from this work must be that lead time
contributes a considerable observed increase in incidence
in screening age groups and that for an estimate of over-
diagnosis to be reliable, it must correct for lead time.
Secondly, the results give us some qualifications to the
use of common methods of correction for lead time and
suggest that correction for lead time in our estimates
and those of others may be inadequate [2,3,5,6]. The
method of considering incidence up to an age in excess
of the upper age limit for screening can be reliable but
Table 5 Incidence rates per 100,000 person-years in the
screened and unscreened populations
Age Population Calendar period, years
group, years 1-5 6-10 11-15 16-20 21-25 26-30
50-54 Screened 406 259 365 259 143 166
Unscreened 166 166 166 166 166 166
55-59 Screened 379 176 258 175 94 180
Unscreened 186 186 186 186 186 186
60-64 Screened 381 169 242 164 91 190
Unscreened 213 213 213 213 213 213
65-69 Screened 441 196 285 193 97 204
Unscreened 229 229 229 229 229 229
70-74 Screened 190 104 110 125 125 223
Unscreened 251 251 251 251 251 251
75-79 Screened 267 250 228 246 236 246
Unscreened 267 267 267 267 267 267
Figure 2 Expected cumulative incidence over 25 years in a screened group of ages 50 to 54 and in an unscreened group of age 55 to
59 at recruitment at the start of follow-up.
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only if more than two decades of follow-up are available.
From Table 4, with incidence to age 74, the excess from
lead time alone at 20 years was 18%. With incidence to
age 79, the excess at 20 years was 14%. It is only at 25
to 30 years of follow-up that the excess incidence
decreased to a figure close to zero.
It should be noted that our estimates pertain to a
population that is 100% screened. In the screening trials,
results are usually given for the group randomly
assigned to the offer of screening, which will contain
some non-attenders. Both lead-time effects and over-
diagnosis will be smaller in an invited group, and the
attenuation depends on the proportion of non-attenders.
At the end of 10 years, from lead time alone there was
an excess cumulative incidence at ages 50 to 79 of 25%
in the screened population. Kalager and colleagues [5],
who used this method of controlling for lead time,
observed an 18% excess incidence in the Norwegian
breast screening program at approximately 10 years.
With 77% participation in the Norwegian program [5],
one would expect 19% (0.77 × 25%) at 10 years. Thus,
all of the excess incidence in that study might be
explained by lead time. The excess incidence in the
screened ages at a follow-up of only 10 years amounts
to 52,020 cases, whereas the deficit above the screened
ages is only 12,962 cases (Table 4). In the age group of
70 to 79 in the first 10 years, 70% of the cancers diag-
nosed are in women who have never been screened
(Table 3). Our study [3] had a 15-year follow-up, but
even at 15 years, our results here indicate that there
would still be residual lead-time effects when this type
of correction is used.
We assumed that the incidence rates would have
remained stable over time in the absence of screening,
for simplicity of calculation. If we had assumed that
underlying incidence rates were increasing, as indeed
they were almost everywhere in the world in the late
20th century, the effect of lead time and the potential to
overestimate overdiagnosis would have been even greater.
Our lead-time model is based on the exponential
sojourn time model of Walter and Day [15], whose arti-
cle gives a full discussion of the mathematical details
and modeling assumptions involved in estimating cancer
screening parameters. Walter and Day gave a range of
estimates of the mean preclinical screen detectable per-
iod from 1.7 to 3.1 years; however, more recent esti-
mates have been close to our estimate of 40 months
[13-16].
The recent UK review of breast cancer screening esti-
mated overdiagnosis of 10% to 20% depending on the
denominator used, from the difference between study
and control group incidence in three of the randomized
screening trials [16]. For two of the trials, the incidence
extended only 6 years beyond the end of screening in
the study group, so the overdiagnosis estimates in the
review are also likely to be overestimates.
Similarly, the attempt by Kalager and colleagues [5] to
control for lead time by comparing the screened popula-
tion with subjects in the unscreened population who are
2 to 5 years older is inadequate for adjusting for lead
time. Our results show that at 10 years, even with the 5-
year adjustment, lead time would confer a 37% increase
in incidence. Correcting for the participation rate of
77%, we would expect a 28% increase in incidence, and
the increase observed by Kalager and colleagues [5] was
actually smaller than this (18%).
Morrell and colleagues [6] applied a similar 5-year
aging correction for lead time in the New South Wales
breast screening program and observed a 30% excess
incidence after adjustment, and at about 10 years after
the program started, with 60% participation. From lead
time alone, we would expect a 22% increase (0.6 × 37%),
suggesting that overdiagnosis accounts for an 8% excess
and that the remainder of the 30% is a residual lead-
time effect. It is also worth noting that the estimate by
Morell and colleagues [6] is not based on cumulative
incidence but only on the three years from 1999 to 2001
when the program was mature. More importantly, it is
worth noting that the estimate of more than 30% over-
diagnosis in the UK program by Jørgensen and Gøtzsche
[2] has no adjustment for lead time at all and therefore
cannot be regarded as a reliable estimate of
overdiagnosis.
Further empirical evidence that overdiagnosis is a
smaller problem than generally thought comes from the
Swedish Two-County Trial of breast cancer screening.
In one county, the cumulative incidence over 29 years
was identical between study and control groups [17].
Since the control group was subject to screening 7 years
later than the study group, this does not rule out over-
diagnosis, but the fact that a population experiencing an
additional 100,000 screening episodes had no increase
whatsoever in incidence suggests that overdiagnosis is a
minor phenomenon.
It should be noted that our estimates are based on
incidence of invasive cancer only. We have blocked the
time into discrete years and posited simultaneous
screening of all subjects rather than a screening round
taking several months to cover the population. Also, it
could be argued that the average sojourn time (the
duration of the preclinical screen detectable period), and
therefore lead time, is smaller than used in our esti-
mates. We did, however, use an estimate of just over 3
years, which is commonly observed for ages of 50 or
more [13,14,18,19]. Indeed, some colleagues have esti-
mated considerably greater sojourn times, albeit with
lesser sensitivity [20]. Also, the general point will still
hold that lead time confers an excess incidence even
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with the common corrections used up to 20 years after
the program starts. Improvements to screening technol-
ogy may change the sojourn time and sensitivity para-
meters. However, they are likely to increase rather than
reduce lead time, so the qualitative implications of our
results will remain relevant. It should also be noted that
although we posited an average lead time of 40 months,
the range of individual values is wide. For example, 35%
of cancers that would have occurred 3 to 4 years after a
screen have their diagnosis advanced to the screening
year.
We estimated effects on incidence of lead time alone.
Of course, there will be other influences, including
changes in underlying incidence because of trends in
risk factor exposure and because of overdiagnosis. How-
ever, our results show that estimation of either of the
latter will be contaminated by lead time unless there is
very long (greater than two decades) observation. The
major implication of this is that it is easy to overesti-
mate overdiagnosis, particularly in uncontrolled observa-
tion of incidence before and after screening. To avoid
such overestimation, it is necessary to estimate lead
time explicitly or to have a very long period of observa-
tion. To conclude that large numbers of breast cancers
would never progress in the absence of treatment is a
major biological leap of faith, and every effort should be
made to rule out alternative explanations of increases in
breast cancer incidence.
Conclusions
The results here indicate that to estimate overdiagnosis
using either the compensatory drop above the age range
for screening or an age inflation, very-long-term follow-
up is required to avoid bias from residual lead-time
effects. Previous estimates of overdiagnosis are likely to
be overestimates.
Appendix
Estimation of proportions of cancers with diagnosis time
shifted by screening, by year since screen
Let l0 be the instantaneous rate of transition from no
detectable disease to presymptomatic screen-detectable
breast cancer, and l1 the subsequent rate of transition
to symptomatic disease. With an exponential distribu-
tion of time to each transition [13], the probability of
clinical symptomatic disease between time 0 and time 1
year, in a person screened negative at time 0, is
P1 =
1
∫
0
λ0e−λ0u
(
1 − e−λ1(1−u)) du = 1 − e−λ0 − λ0e−λ1
1
∫
0
e(λ1−λ0)udu
= 1 − e−λ0 − λ0(e
−λ0 − e−λ1 )
(λ1 − λ0)
This is essentially the probability of transition from no
detectable disease to presymptomatic including the pos-
sibilities of remaining presymptomatic or progressing to
symptomatic disease MINUS the probability of transi-
tion only to the presymptomatic phase. This difference
is equal to the probability of transition from no detect-
able disease to symptomatic disease. Suppose an inci-
dence of 2 per thousand per year. The corresponding
value for l0 would be 0.002 (corresponding to an inci-
dence of 2 per thousand person-years) and l1 = 0.3
(corresponding to a mean sojourn time of 40 months),
this probability is 0.000272, 14% of the expected inci-
dence (0.000272/0.002 = 0.14). Thus 86% of the
tumours expected to arise in the first year after screen-
ing have their diagnosis advanced to the time of the
screen.
The probability of symptomatic incidence in years 0 to
2 is correspondingly
P2 = 1 − e−2λ0 − λ0(e
−2λ0 − e−2λ1 )
(λ1 − λ0)
With l0 = 0.002 and l1 = 0.3, this would be 0.000991.
Therefore, the probability of symptomatic occurrence
between 1 and 2 years after the screen would be
0.000991-0.000272 = 0.000719, 36% of the expected
incidence in the absence of screening. Thus 64% of the
tumours which would have arisen in the second year
after screening have their diagnosis advanced to the
time of the screen. Proportions for subsequent years are
calculated similarly.
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